This single-center study in healthy adults evaluates the pharmacokinetics and absorption of single doses of NMNH-Ca and NAM. Participants receive different treatments in crossover groups over time to assess how the body absorbs, processes, and eliminates these substances.

A Prospective, Single center, Interventional, Single dose, Multiple-arm, Randomized, Open -label, Cross-over, Clinical study to evaluate pharmacokinetics of NMNH-Ca & NAM in healthy adult participants. - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/07/113649

Enrollment

Registered

2026-07-07

Start date

Unknown

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: NMNH-Ca & NAM: Reduced beta-Nicotinamide Mononucleotide Calcium Salt (NMNH-Ca) & Nicotinamide (NAM) For 6 weeks Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: 1.Adult healthy male/females aged 40 to 65 years. 2.Participants with Body Mass Index (BMI) between 18.5 and 35 kg/m2. 3.Participants who are willing to provide written Informed Consent for participating in the study. 4.Participants who are able to follow verbal and written study directions. 5.Participants must be willing to agree to use effective contraceptive methods while on treatment and for 3 months after the completion of study. 6.Participants willing to administer assigned dietary supplements for the study duration.

Exclusion criteria

Exclusion criteria: Participants will be excluded from the study if they are currently using, or have recently used within 14 days prior to enrolment, any form of nicotinic acid, niacin, nicotinamide mononucleotide, nicotinamide riboside, other NAD+ precursors, vitamin B3, or related derivatives. Individuals taking statin medications or those who have used tobacco products or recreational drugs within the past six months are also ineligible. Participants with abnormal laboratory test results at screening, or any condition that, in the investigator s judgment, may interfere with study participation, will be excluded. The study further excludes individuals with a history or active diagnosis of chronic diseases affecting major systems, including urinary, cardiovascular, neuroendocrine (such as diabetes), immune, central nervous, hematopoietic, gastrointestinal, hepatic, or visual systems, as well as hereditary or systemic disorders. Those with recent infections, allergies, or positive tests for HIV, hepatitis B or C, or syphilis are not eligible. Additional exclusions include a history of substance abuse, unstable mental health conditions, or unwillingness to stop supplements prior to the study. Participants must not be on weight loss programs, chronic interfering medications, or incompatible schedules. Pregnant or breastfeeding women, individuals hypersensitive to study compounds, those in other trials, unable to provide blood samples, or with cancer within the past five years are also excluded.

Design outcomes

Primary

Measure	Time frame
To determine pharmacokinetic profile of multiple doses of NMNH-Ca and NAM in blood.Timepoint: Enrolment/Visit 2: Day 1 Visit 3 (Day 9), Visit 4 (Day 17), Visit 5 (Day 25), Visit 6 (Day 33), EOS/ Visit 7 (Day 41)	—

Secondary

Measure	Time frame
To evaluate pharmacokinetics of multiple doses of NMNH-Ca & NAM in urine.Timepoint: Enrolment/Visit 2: Day 1 Visit 3 (Day 9), Visit 4 (Day 17), Visit 5 (Day 25), Visit 6 (Day 33), EOS/ Visit 7 (Day 41)	—

Countries

India

Contacts

Public ContactBrindha Arumugam

Medstar Specialist Hospital

medstarhospitalbng@gmail.com7995114352

Outcome results